{"organizations": [], "uuid": "b91ad1f6a91513438689bc12bfdb6c37fae85208", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180302.html", "section_title": "Archive News &amp; Video for Friday, 02 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-herantis-pharma-h2-net-loss-at-eur/brief-herantis-pharma-h2-net-loss-at-eur-136700-idUSFWN1QK00Y", "country": "US", "domain_rank": 408, "title": "BRIEF-Herantis Pharma H2 Net loss at EUR 136,700", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.035, "site_type": "news", "published": "2018-03-02T15:08:00.000+02:00", "replies_count": 0, "uuid": "b91ad1f6a91513438689bc12bfdb6c37fae85208"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-herantis-pharma-h2-net-loss-at-eur/brief-herantis-pharma-h2-net-loss-at-eur-136700-idUSFWN1QK00Y", "ord_in_thread": 0, "title": "BRIEF-Herantis Pharma H2 Net loss at EUR 136,700", "locations": [], "entities": {"persons": [{"name": "parkinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "herantis pharma oyj", "sentiment": "negative"}, {"name": "brief-herantis pharma", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 2 (Reuters) - Herantis Pharma Oyj:\n* ‍HERANTIS DOES NOT EXPECT ESSENTIAL REVENUES IN 2018​ * ‍CONTINUES TO INVEST IN ITS ONGOING DEVELOPMENT PROGRAMS IN SECONDARY LYMPHEDEMA AND PARKINSON’S DISEASE​\n* ‍MAIN OBJECTIVES FOR 2018 ARE LAUNCHING A PHASE 2 CLINICAL STUDY WITH COMPANY’S DRUG CANDIDATE LYMFACTIN®​\n* ‍MAIN OBJECTIVES FOR 2018 ARE COMPLETING PATIENT RECRUITMENT IN PHASE 1-2 CLINICAL STUDY WITH CDNF​\n* ‍DID NOT HAVE ESSENTIAL REVENUES IN 2017 OR IN CORRESPONDING PERIOD IN PREVIOUS YEAR​\n* H2 NET LOSS EUR 136,700 VERSUS LOSS EUR 1.8 MILLION YEAR AGO\n* PROPOSES ‍THAT NO DIVIDEND SHALL BE PAID FOR FINANCIAL PERIOD JANUARY 1-DECEMBER 31, 2017.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-02T15:08:00.000+02:00", "crawled": "2018-03-03T17:29:27.001+02:00", "highlightTitle": ""}